Background: T cell plays a crucial role in the occurrence and progression of Skin cutaneous melanoma (SKCM). This research aims to identify the actions of T cell proliferation-related genes (TRGs) on the prognosis and immunotherapy response of tumor patients. Method: The clinical manifestation and gene expression data of SKCM patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. T cell proliferation-related molecular subtypes were identified utilizing consensus clustering. Subsequently, Cox and Lasso regression analysis was conducted to identify six prognostic genes, and a prognostic signature was constructed. A series of experiments, such as qRT-PCR, Western blotting and CCK8 assay, were then conducted to verify the reliability of the six genes. Results: In this study, a grading system was established to forecast survival time and responses to immunotherapy, providing an overview of the tumoral immune landscape. Meanwhile, we identified six prognostic signature genes. Notably, we also found that C1RL protein may inhibit the growth of melanoma cell lines. Conclusion: The scoring system depending on six prognostic genes showed great efficiency in predicting survival time. The system could help to forecast prognosis of SKCM patients, characterize SKCM immunological condition, assess patient immunotherapy response.

BackgroundHemoporfin‐mediated photodynamic therapy (HMME‐PDT) is currently considered one of the most promising therapies for port‐wine stain (PWS). However, the efficacy of this is very variable and needs further studies.MethodsA total of 101 patients with PWS in the face, neck, or extremities who received at least 2 HMME‐PDT sessions were included in the study, and correlations of efficacy with age, gender, locations, treatment sessions, and PDL treatment history were analyzed.ResultsThe efficacy of HMME‐PDT in patients with different ages, locations, and different numbers of prior PDL treatment showed constantly significant differences after 1/2/last session (p < .05). The number of treatments was associated with efficacy, and patients who received more than two sessions had a better response than those who underwent two sessions only (p < .001). Ordinal logistic regression analysis confirmed the above‐mentioned associations. Nevertheless, patients of different sex, subtype, and lesion size showed no significant differences.ConclusionsOur studies demonstrated that HMME‐PDT is effective in the treatment of PWS. The more prior PDL treatments, older age, lips involvement, PWS on limbs were adverse factors for Hemoporfin‐PDT, while multiple HMME‐PDT sessions can improve effective and response rate. Besides, ambient temperature and lesions temperature should be concerned, local cooling provides some relief from pain but may influence effect.

Background Secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis with the documented adverse effects. Here we reported in one case that a new symptom, Prurigo Nodularis (PN), developed during the programmed dosing of secukinumab. Case introduction A 22-years-old male with a 6-month history of severe plaque psoriasis vulgaris was presented to the dermatology clinic two weeks after the fifth serial weekly doses of secukinumab, for the reason of the outbreaks of multiple erythematous papules and pruritus nodules on the trunk and extremities. Physical examination showed that psoriatic rash were under effective control with the previous targeted therapy of secukinumab for plaque psoriasis vulgaris, but new dermatologic condition was spotted with multiple edematous red firm papules on the trunk and extremities, in the form of soy or hemispherical nodules, red in color, firm to touch, with some ulcerated crusts visible at tops, but negative Auspitz sign. Pathological examination confirmed these papules as PN. Conclusion This case report is shared to inform clinicians about an unannounced adverse effect of the secukinumab in the treatment of psoriasis, and it is recommended that patients be carefully informed of the possible risk of PN before starting treatment.

Background: secukinumab has been approved by the U.S. FDA and the European Medicines Agency for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Here we report a case of prurigo nodularis during the treatment of psoriasis with secukinumab, which has never been reported before. Case introduction: the patient was a 22-years-old male with a 6-month history of severe plaque paoriasis vulgaris, who received regular treatment with satisfactory control of the psoriatic rash, and was seen for 1 week for red papules and nodules with pruritus on the trunk and extremities. Dermatologic condition: multiple edematous red firm papules on the trunk and extremities in the form of soy or hemispherical nodules, with some tops visible as ulcerated crusts, red in color, firm to touch, and negative Auspitz sign. Pathological examination confirmed prurigo nodularis (PN). Conclusion: This case is shared to inform clinicians about yet another adverse effect of the IL-17A inhibitor in the treatment of psoriasis. It is recommended that patients be carefully informed of the possible risk of prurigo nudularis before starting treatment.